An organic compound is represented by general formula (1) below: ##STR00001## where X.sub.1 and X.sub.2 are each independently selected from the group consisting of an alkyl group, an aryl group, and an aralkyl group; R.sub.11 to R.sub.16 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, a heterocyclic group, and a halogen atom; R.sub.21 and R.sub.22 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an aryl group, and an aralkyl group; and A.sub.1.sup.− and A.sub.2.sup.− each independently represent a monovalent anion.

The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.

This application relates to a lithium-ion secondary battery. A positive electrode plate of the lithium-ion secondary battery includes a positive electrode active substance LiNi.sub.xCo.sub.yN.sub.zM.sub.1-x-y-zO.sub.2, with N selected from Mn and Al, and M selected from any one of Co, Ni, Mn, Mg, Cu, Zn, Al, Sn, B, Ga, Cr, Sr, V, and Ti, where 0.5≤x<1, 0≤y≤1, 0≤z≤1, and x+y+z≤1; and an electrolyte of the lithium-ion secondary battery contains a specified amount of compounds represented by formula (1), formula (2), and formula (3). The lithium-ion secondary battery of this application has both high energy density and high thermal stability. This application further relates to a battery module containing the lithium-ion secondary battery, a battery pack, and an electric apparatus.

##STR00001##

This application relates to a lithium-ion secondary battery. A positive electrode plate of the lithium-ion secondary battery includes a positive electrode active substance LiNi.sub.xCo.sub.yN.sub.zM.sub.1-x-y-zO.sub.2, with N selected from Mn and Al, and M selected from any one of Co, Ni, Mn, Mg, Cu, Zn, Al, Sn, B, Ga, Cr, Sr, V, and Ti, where 0.5≤x<1, 0≤y≤1, 0≤z≤1, and x+y+z≤1; and an electrolyte of the lithium-ion secondary battery contains a specified amount of compounds represented by formula (1), formula (2), and formula (3). The lithium-ion secondary battery of this application has both high energy density and high thermal stability. This application further relates to a battery module containing the lithium-ion secondary battery, a battery pack, and an electric apparatus.

##STR00001##

The present invention relates to a polycyclic aromatic derivative compound that can be employed in an organic layer in a device, and an organoelectroluminescent device with high-efficiency and a long-life, including same and having remarkably improved luminous efficiency, and the device employing same can be efficiently utilized in a variety of displays and lighting devices, such as a flat panel display device, a flexible display device, a single color or white flat lighting device, and a single color or white flexible lighting device.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I):

##STR00001##

including stereoisomers, salts and tautomers thereof, wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5, L.sup.6, M.sup.1, M.sup.2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

The invention relates to prodrug compounds of formula I: ##STR00001##
wherein R.sup.2, R.sup.3, R.sup.5, R.sup.7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.

The invention relates to prodrug compounds of formula I: ##STR00001##
wherein R.sup.2, R.sup.3, R.sup.5, R.sup.7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.

The present application relates to a polycyclic compound including nitrogen and an organic light emitting device including the same.

Disclosed are a heterocyclic compound and an organic light emitting device including the same.